文献速递糖尿病

无管路体表自动化胰岛素输注系统与无管路体表传感器增强泵在1型糖尿病中的比较:多中心随机对照试验

Comparison between a tubeless, on-body automated insulin delivery system and a tubeless, on-body sensor-augmented pump in type 1 diabetes: a multicentre randomised controlled trial.
PubMed 文献 · Diabetologia · 2024-04-18

该多中心平行组随机对照试验在韩国13家三级医疗中心纳入104例1型糖尿病成人,1:1分配至无管路体表自动化胰岛素输注(AID)系统组或无管路体表传感器增强泵(SAP)组治疗12周。主要结局为目标范围内时间(TIR)百分比,AID组较SAP组 adjusted means 差异为6.5%(95%CI 3.6%,9.4%),p<0.001;两组均未发生糖尿病酮症酸中毒或严重低血糖。

要点

  • 无管路体表AID系统较无管路体表SAP显著改善TIR,adjusted means 差异6.5%(95%CI 3.6%,9.4%),p<0.001
  • AID组TIR从基线62.1±17.1%升至12周71.5±10.7%,SAP组从64.7±17.0%升至66.9±15.0%
  • 两组均未发生糖尿病酮症酸中毒或严重低血糖事件

核心结论

  • 无管路体表AID系统的使用是安全的,且与无管路体表SAP相比,与更优的血糖谱相关,包括TIR、目标范围下时间、目标范围上时间和CV。

研究设计与样本

  • 多中心、平行组、随机对照试验,在韩国13家三级医疗中心开展。
  • 纳入19-69岁、HbA1c<85.8 mmol/mol(<10.0%)的1型糖尿病成人,1:1分配至无管路体表AID系统(干预组)或无管路体表SAP(对照组)治疗12周。
  • 由独立统计师进行分层区组随机化,因干预性质无法设盲。
  • 共104例参与者接受随机化,干预组53例,对照组51例;参与者平均(±SD)年龄40±11岁。
  • 主要结局为连续血糖监测测得的血糖在3.9-10.0 mmol/l范围内的时间百分比(TIR);采用以基线值和研究中心为协变量的ANCOVA分析。

主要发现

  • 干预组平均(±SD)TIR从基线62.1±17.1%升至12周试验期间的71.5±10.7%,对照组从64.7±17.0%升至66.9±15.0%(adjusted means 差异:6.5% [95%CI 3.6%,9.4%],p<0.001)。
  • 干预组目标范围下时间、目标范围上时间、CV和平均血糖水平也显著优于对照组。
  • 干预组HbA1c从基线50.9±9.9 mmol/mol(6.8±0.9%)降至12周后45.9±7.4 mmol/mol(6.4±0.7%),对照组从48.7±9.1 mmol/mol(6.6±0.8%)降至45.7±7.5 mmol/mol(6.3±0.7%)(adjusted means 差异:-0.7 mmol/mol [95%CI -2.0,0.8 mmol/mol](-0.1% [95%CI -0.2%,0.1%]),p=0.366)。
  • 两组均未发生糖尿病酮症酸中毒或严重低血糖事件。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: This study compares the efficacy and safety of a tubeless, on-body automated insulin delivery (AID) system with that of a tubeless, on-body sensor-augmented pump (SAP). METHODS: This multicentre, parallel-group, RCT was conducted at 13 tertiary medical centres in South Korea. Adults aged 19-69 years with type 1 diabetes who had HbA1c levels of <85.8 mmol/mol (<10.0%) were eligible. The participants were assigned at a 1:1 ratio to receive a tubeless, on-body AID system (intervention group) or a tubeless, on-body SAP (control group) for 12 weeks. Stratified block randomisation was conducted by an independent statistician. Blinding was not possible due to the nature of the intervention. The primary outcome was the percentage of time in range (TIR), blood glucose between 3.9 and 10.0 mmol/l, as measured by continuous glucose monitoring. ANCOVAs were conducted with baseline values and study centres as covariates. RESULTS: A total of 104 participants underwent randomisation, with 53 in the intervention group and 51 in the control group. The mean (±SD) age of the participants was 40±11 years. The mean (±SD) TIR increased from 62.1±17.1% at baseline to 71.5±10.7% over the 12 week trial period in the intervention group and from 64.7±17.0% to 66.9±15.0% in the control group (difference between the adjusted means: 6.5% [95% CI 3.6%, 9.4%], p<0.001). Time below range, time above range, CV and mean glucose levels were also significantly better in the intervention group compared with the control group. HbA1c decreased from 50.9±9.9 mmol/mol (6.8±0.9%) at baseline to 45.9±7.4 mmol/mol (6.4±0.7%) after 12 weeks in the intervention group and from 48.7±9.1 mmol/mol (6.6±0.8%) to 45.7±7.5 mmol/mol (6.3±0.7%) in the control group (difference between the adjusted means: -0.7 mmol/mol [95% CI -2.0, 0.8 mmol/mol] (-0.1% [95% CI -0.2%, 0.1%]), p=0.366). No diabetic ketoacidosis or severe hypoglycaemia events occurred in either group. CONCLUSIONS/INTERPRETATION: The use of a tubeless, on-body AID system was safe and associated with superior glycaemic profiles, including TIR, time below range, time above range and CV, than the use of a tubeless, on-body SAP. TRIAL REGISTRATION: Clinical Research Information Service (CRIS) KCT0008398 FUNDING: The study was funded by a grant from the Korea Medical Device Development Fund supported by the Ministry of Science and ICT; the Ministry of Trade, Industry and Energy; the Ministry of Health and Welfare; and the Ministry of Food and Drug Safety (grant number: RS-2020-KD000056).

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Kim JY, Jin SM, Kang ES, et al. Comparison between a tubeless, on-body automated insulin delivery system and a tubeless, on-body sensor-augmented pump in type 1 diabetes: a multicentre randomised controlled trial. Diabetologia. 2024. PMID: 38634887. doi:10.1007/s00125-024-06155-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。